Summary

• IMU Biosciences has begun profiling an initial 80,000 UK Biobank blood samples, comprising 40,000 new samples and 40,000 from cryopreserved collections.
• Ultima Genomics' UG200 sequencing platform and single-cell technology supplied through Waters will contribute molecular data to the programme.
• The resulting information is intended to become available to approved UK Biobank researchers, with wider profiling across the 500,000-participant cohort remaining a longer-term ambition.

UK Biobank is adding detailed immune system measurements to its research database, with an initial 80,000 blood samples being profiled to help scientists investigate the connections between immune activity, disease, ageing, and long-term health outcomes.

The programme involves UK-based IMU Biosciences, sequencing technology company Ultima Genomics, and single-cell analysis technology supplied through Waters Corporation. It will generate biological information that researchers can examine alongside the genetic, clinical, imaging, and lifestyle records already collected from UK Biobank participants.

IMU began profiling samples in September, while Ultima confirmed on 19 October that its UG200 sequencing platform had been selected for the study. The initial programme comprises 40,000 newly collected samples and another 40,000 obtained from UK Biobank’s cryopreserved collection.

IMU Biosciences eventually wants to extend the work across the approximately 500,000 people participating in UK Biobank. That broader ambition remains separate from the current 80,000-sample programme and has not been presented as a completed or fully contracted expansion.

Immune measurements add another biological dimension

UK Biobank has built an unusually extensive record of human health since recruiting volunteers between 2006 and 2010.

Participants provided biological samples and information about their lifestyles and health, while subsequent research has added genetic sequencing, imaging, laboratory measurements, and medical records extending across almost two decades.

Those records allow scientists to investigate relationships between characteristics observed earlier in life and health outcomes occurring years later.

Despite that depth of information, detailed profiling of immune cell populations has not previously been available across a comparable proportion of the cohort.

The immune system contains numerous interacting cell populations with different functions. Their composition and activity can vary according to age, infection, medication, genetics, and other characteristics.

Measuring only a small set of conventional markers may overlook differences between populations that appear similar when considered together.

IMU’s High Definition Immunology platform is designed to distinguish up to 2,500 immune cell subsets, generating more than 100 million data points from a small blood sample, according to the company’s description of its technology.

Those figures concern the analytical capabilities of the platform rather than clinically validated interpretations for every measurement.

The challenge is to establish which observed differences represent ordinary biological variation and which may be associated with future disease or other important outcomes.

A detailed immune profile has limited predictive value without appropriate comparisons. Researchers need enough samples to distinguish patterns associated with factors such as age and sex from those that could indicate an emerging health condition.

UK Biobank’s large participant cohort and extensive records provide a way to examine those relationships without relying on isolated immune measurements.

Stored samples connect biology with medical history

The inclusion of 40,000 cryopreserved samples creates a different research opportunity from analysing recently collected blood.

Some of the stored material originated during earlier phases of UK Biobank’s work. Researchers can potentially examine immune characteristics in those samples alongside clinical events recorded during subsequent years.

For example, a particular immune cell pattern could be investigated for an association with a condition that developed after the original sample was collected.

Such an association might identify a possible research marker, but it would not establish that the immune characteristic caused the disease or could reliably predict its development in an individual patient.

Researchers must account for differences in sample age, storage conditions, handling procedures, and other technical factors that could influence measurements.

Cryopreserved biological material is also a finite resource. Using older samples consumes material that may have been retained for many years and cannot necessarily be replaced under the same original conditions.

IMU has emphasised the importance of standardised handling and analysis, with measurements produced using consistent processes so that results generated at different times can be compared meaningfully.

Maintaining that consistency across tens of thousands of samples will be an important part of determining the dataset’s future research value.

Sequencing provides a second layer of information

The project also incorporates single-cell molecular analysis, examining biological activity at the level of individual cells rather than relying only on measurements averaged across a complete sample.

Ultima’s UG200 sequencing platform has been selected to support that work, alongside the BD Rhapsody Single-Cell Platform provided through Waters Corporation.

Sequencing can reveal patterns of gene expression within different immune cell populations, helping researchers examine how cells are functioning in addition to identifying their characteristics.

Combining these data types could support investigations into how immune cell populations respond to biological changes and how those responses relate to other information held by UK Biobank.

The sequencing systems must operate with suitable consistency and throughput for a study of this size. Sample preparation, laboratory processing, quality control, and data analysis all influence the overall cost and reliability of the resulting information.

Ultima’s selection follows its involvement in other large biomedical datasets, including UK Biobank’s separate proteomics work. Those projects concern different measurements and should not be combined into one participant or sample total.

The latest immune study is not a clinical deployment of Ultima’s equipment for diagnosing disease. Its purpose is to generate research data that may support future scientific investigations.

AI research depends on consistent biological data

IMU says the first 10,000 samples are being supported through a UK Sovereign AI grant, with additional single-cell transcriptomic measurements planned from the same donors.

The company is seeking to generate a dataset in which immune profiles can be connected with genetic, imaging, environmental, and clinical information already held by UK Biobank.

Such combinations may be useful when training AI models to investigate biological relationships that are difficult to identify through conventional analyses.

However, large datasets do not automatically produce reliable predictive models. Differences in laboratory procedures, sample processing, and instrument behaviour can introduce patterns that software mistakes for genuine biology.

Models can also identify statistical associations that do not reflect causal relationships, particularly where characteristics such as age, medical history, or treatment are correlated with the condition being studied.

The research programme aims to reduce some of those problems through consistent profiling within one established cohort, although the quality of the resulting models will still require independent assessment.

AI applications developed from the information would also need to be evaluated against appropriate research or clinical standards before claims about diagnostic accuracy or treatment decisions could be justified.

No new clinical test, therapy, or validated patient-level prediction has been announced as an outcome of the project.

Access extends beyond the companies generating the data

Once the profiling work is completed and the information prepared for research use, IMU intends to return the resulting dataset to UK Biobank.

Approved researchers would then be able to access the immune measurements through UK Biobank’s established procedures without having to obtain them directly from IMU.

That arrangement could allow academic groups, pharmaceutical researchers, and other authorised organisations to investigate questions extending beyond those initially considered by the project partners.

Possible uses include studying immune ageing, the biological mechanisms associated with disease, and differences in responses to treatment.

However, the planned access does not amount to unrestricted publication of participants’ individual records. UK Biobank maintains requirements governing research applications and the responsible use of participant information.

The commercial relevance is partly connected to drug discovery, where better immune information could inform research into biological pathways and potential treatment targets.

Those applications remain prospective, and the announcement provides no measured evidence that the new dataset has already improved drug development or clinical outcomes.

With profiling under way, the immediate milestones are the production of consistent measurements, integration with existing research records, and eventual release through UK Biobank’s approved access arrangements.

The programme will be judged by the quality and usefulness of that shared resource, rather than the number of data points its laboratory systems can generate alone.